Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50 to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes

Hidekatsu Yanai, Taro Yoshimi, Ritsuko Honda


The glucagon-like peptide 1 (GLP-1) stimulates insulin secretion from pancreatic ?-cells in a glucose-dependent manner. Therapeutic strategies for type 2 diabetes mellitus are focused on the use of GLP-1 analogues. Liraglutide, an acylated analogue of human GLP-1, has been introduced in Japan in 2010. We will show a 70-year-old woman with type 2 diabetes mellitus achieving a good glycemic control by switching from twice-daily pre-mixed insulin 50/50 to liraglutide. Measurements of plasma glucose and serum C-peptide levels before and after each meal ingestion and daily urinary C-peptide levels suggested that liraglutide ameliorates glucose metabolism mainly not by the glucose-dependent insulinotropic effect but by amelioration in insulin sensitivity. Furthermore, results from a glucagon-loading test indicated that liraglutide reduced plasma glucose levels not by enhancing insulin secretion but by suppressing glucagon-mediated hepatic glucose output.

J Med Cases. 2011;2(2):76-80
doi: https://doi.org/10.4021/jmc143w


C-peptide; Glucagon-like peptide-1; Glucagon-loading test; Obesity; Pre-mixed insulin

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.